Literature DB >> 31079224

Functional Status of Patients with COPD Assessed by London Chest Activity of Daily Living Scale: Gender Association and Validity of a Cutoff Point.

Letícia Fernandes Belo1, Antenor Rodrigues1,2, Thaís Paes1, Felipe Vilaça Cavallari Machado1, Lorena Paltanin Schneider1, Ana Paula Vicentin1, Vanessa Suziane Probst3, Fabio Pitta1, Nidia Aparecida Hernandes4.   

Abstract

PURPOSE: Whether the difference in the impact of chronic obstructive pulmonary disease (COPD) on the functional status of men and women stems from clinical distinctions or to the measuring instrument used is unclear. Like most instruments for assessing functional limitation in COPD, the interpretation of the results of the London Chest Activity of Daily Living (LCADL) scale is limited because a lack of a valid cutoff point to this scale. For that, this study sought to compare the functional status between men and women with COPD; and propose a cutoff point for LCADL capable of discriminating the prognosis of these individuals.
METHODS: A sample of 138 subjects with moderate-severe COPD was evaluated by the LCADL. The percentage of the individual maximum score was used to obtain a cutoff point capable of discriminating patients with the worse prognosis according to the BODE Index. The cutoff point was also tested in an independent sample (n = 70).
RESULTS: Regarding the total score, domestic and leisure domains of the LCADL, men had better scores than women (P ≤ 0.01). The cutoff point found was 37% (area under the curve = 0.70, 95% confidence interval = 0.60-0.80, sensitivity = 0.55 and specificity = 0.74). Individuals who scored ≥ 37% had a worse prognosis and level of physical activities of daily living than those who scored below (P ≤ 0.02).
CONCLUSION: When evaluated by the LCADL, men and women with COPD present difference in the functional status. The established cutoff point (37%) adequately discriminates individuals regarding the prognosis, contributing to improve the interpretation capacity of the LCADL.

Entities:  

Keywords:  Activities of daily living; Chronic obstructive pulmonary disease; Surveys and questionnaires; Symptom assessment

Mesh:

Year:  2019        PMID: 31079224     DOI: 10.1007/s00408-019-00235-2

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  29 in total

1.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

2.  Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study.

Authors:  Benjamin Waschki; Anne Kirsten; Olaf Holz; Kai-Christian Müller; Thorsten Meyer; Henrik Watz; Helgo Magnussen
Journal:  Chest       Date:  2011-01-27       Impact factor: 9.410

3.  Measurement properties of the SenseWear armband in adults with chronic obstructive pulmonary disease.

Authors:  Kylie Hill; Thomas E Dolmage; Lynda Woon; Roger Goldstein; Dina Brooks
Journal:  Thorax       Date:  2010-06       Impact factor: 9.139

4.  Relationship between daily living activities (ADL) limitation and the BODE index in patients with chronic obstructive pulmonary disease.

Authors:  Karen M Simon; Marta F Carpes; Krislainy S Corrêa; Karoliny dos Santos; Manuela Karloh; Anamaria F Mayer
Journal:  Rev Bras Fisioter       Date:  2011 May-Jun

Review 5.  Improving the Management of COPD in Women.

Authors:  Christine R Jenkins; Kenneth R Chapman; James F Donohue; Nicolas Roche; Ioanna Tsiligianni; MeiLan K Han
Journal:  Chest       Date:  2016-11-02       Impact factor: 9.410

6.  Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL).

Authors:  R Garrod; J C Bestall; E A Paul; J A Wedzicha; P W Jones
Journal:  Respir Med       Date:  2000-06       Impact factor: 3.415

Review 7.  An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease.

Authors:  Anne E Holland; Martijn A Spruit; Thierry Troosters; Milo A Puhan; Véronique Pepin; Didier Saey; Meredith C McCormack; Brian W Carlin; Frank C Sciurba; Fabio Pitta; Jack Wanger; Neil MacIntyre; David A Kaminsky; Bruce H Culver; Susan M Revill; Nidia A Hernandes; Vasileios Andrianopoulos; Carlos Augusto Camillo; Katy E Mitchell; Annemarie L Lee; Catherine J Hill; Sally J Singh
Journal:  Eur Respir J       Date:  2014-10-30       Impact factor: 16.671

8.  Gender and COPD in patients attending a pulmonary clinic.

Authors:  Juan P de Torres; Ciro Casanova; Concepción Hernández; Juan Abreu; Armando Aguirre-Jaime; Bartolome R Celli
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

9.  Gender differences in time spent on parenting and domestic responsibilities by high-achieving young physician-researchers.

Authors:  Shruti Jolly; Kent A Griffith; Rochelle DeCastro; Abigail Stewart; Peter Ubel; Reshma Jagsi
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

10.  Minimal detectable change of the London chest activity of daily living scale in patients with COPD.

Authors:  Gianna Waldrich Bisca; Mahara Proença; Alexandre Salomão; Nidia A Hernandes; Fabio Pitta
Journal:  J Cardiopulm Rehabil Prev       Date:  2014 May-Jun       Impact factor: 2.081

View more
  2 in total

1.  No gender-related bias in COPD diagnosis and treatment in Sweden: a randomised, controlled, case-based trial.

Authors:  Hamid Akbarshahi; Zainab Ahmadi; David C Currow; Jacob Sandberg; Zac Vandersman; Aaron Shanon-Honson; Magnus Ekström
Journal:  ERJ Open Res       Date:  2020-11-10

2.  Physical Tests Are Poorly Related to Patient-Reported Outcome Measures during Severe Acute Exacerbations of COPD.

Authors:  Kirsten Quadflieg; Ana Machado; Sarah Haesevoets; Marc Daenen; Michiel Thomeer; David Ruttens; Martijn A Spruit; Chris Burtin
Journal:  J Clin Med       Date:  2021-12-28       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.